Want to take quizzes and track your credits?
The US government is investing in rapid development of vaccines against coronavirus disease 2019 (COVID-19), several relying on new technologies.1 In the US, 4 vaccine candidates are in phase 3 studies with initial results expected soon. If studies succeed, 1 or more vaccines may become available within a few months. Clinicians are likely among the first to be offered COVID-19 vaccines and have a key role in helping patients make decisions about vaccination.2 Providing evidence-based information will be particularly important in an environment of polarization and mistrust. This Viewpoint focuses on common questions patients are likely to ask about COVID-19 vaccines.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Jesse L. Goodman, MD, MPH, Medicine and Infectious Disease, Georgetown University School of Medicine, 3900 Reservoir Rd, Washington, DC 20057 (firstname.lastname@example.org).
Published Online: October 16, 2020. doi:10.1001/jama.2020.20590
Conflict of Interest Disclosures: Dr Goodman reported receiving personal fees and nonfinancial support from GlaxoSmithKline and Intellia Therapeutics, and nonfinancial support from US Pharmacopeia outside the submitted work. Dr Grabenstein reported having stock equity in Merck & Co, consulting fees from Valneva, personal fees from serving on the Janssen advisory board, and personal fees from the VBI advisory board outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank Norman W. Baylor, PhD, Biologics Consulting; Luciana L. Borio, MD, In-Q-Tel; Bruce G. Gellin, MD, MPH, Sabin Vaccine Institute; Peter J. Hotez, MD, PhD, Baylor College of Medicine; Glen J. Nowak, PhD, University of Georgia; Paul A. Offit, MD, Children’s Hospital of Philadelphia; and Walter A. Orenstein, MD, Emory University, for their input and Nicole Lurie, MD, MSPH, Coalition for Epidemic Preparedness Innovations (CEPI), Harvard Medical School, for her helpful review.
Additional Information: Dr Goodman reported that he served as the chief scientist of the FDA from January 2009 to March 2014.
You currently have no searches saved.
You currently have no courses saved.